Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Chlorcyclizine→

Chlorcyclizine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
82-93-9
Molecular formula
C18H21ClN2
Molecular weight
300.8 g/mol
Drug class
First-generation piperazine antihistamineH1 receptor antagonist
Mechanism of action
Competitively antagonises histamine H1 receptors and has anticholinergic activity, reducing allergic symptoms and vestibular-mediated nausea.
Indications / reported uses
  • Symptomatic treatment of allergic rhinitis, pruritus and urticaria in countries where chlorcyclizine products are authorised
  • Prevention or treatment of motion sickness and associated nausea in selected formulations; current availability and indications vary by jurisdiction

Sources: NLM MeSH — Chlorcyclizine · PubMed — Chlorcyclizine antihistamine pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Chlorcyclizine Environmental Risk Assessment (ERA) (the Chlorcyclizine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.